TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
01 mai 2017 08h30 HE
|
TESARO, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
27 avr. 2017 08h15 HE
|
TESARO, Inc.
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration...
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
26 avr. 2017 08h30 HE
|
TESARO, Inc.
VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...
TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017
25 avr. 2017 16h15 HE
|
TESARO, Inc.
WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its first-quarter 2017 financial results on Tuesday, May 9, 2017, after the close of the U.S. financial...
TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.
19 avr. 2017 16h15 HE
|
TESARO, Inc.
ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancerZEJULA is the only PARP inhibitor that has demonstrated a clinically...
Tesaro Wins Awards for Clinical Development Team of the Year and Clinical Partnership of the Year
07 avr. 2017 08h30 HE
|
TESARO, Inc.
WALTHAM, Mass., April 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, has been recognized with two Clinical and Research Excellence (CARE)...
TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cancer
27 mars 2017 15h45 HE
|
TESARO, Inc.
Expanded niraparib ovarian cancer program intended to potentially transform the treatment of front-line ovarian cancerNew breast cancer clinical program for niraparib to address greatest area of unmet...
TESARO Announces Niraparib Data Presentations at the 2017 SGO Annual Meeting on Women’s Cancer
12 mars 2017 08h38 HE
|
TESARO, Inc.
WALTHAM, Mass., March 12, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced two niraparib presentations at the 2017 Society for...
TESARO Announces Fourth-Quarter 2016 Operating Results
28 févr. 2017 16h05 HE
|
TESARO, Inc.
Niraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underwayExpanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H...
TESARO Receives Positive CHMP Opinion for VARUBY®
27 févr. 2017 02h00 HE
|
TESARO, Inc.
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...